TGFB1 and neoplasm: This construct combines a chimeric version of an anti-PD-L1 monoclonal antibody (avelumab) with a fragment of TGF-βR4 to entrap active TGF-β.100 Inhibiting this cytokine could be especially relevant in tumours treated with radiotherapy, as radiotherapy activates the latent form of TGF-β and induces its transcription.101,102